Iradimed (IRMD) Non-Current Deferred Tax Liability (2013 - 2023)

Iradimed (IRMD) posted quarterly Non-Current Deferred Tax Liability of $1.1 million for Q4 2023, up 78.48% on a QoQ basis from $611269.0 in Q4 2018.

Iradimed (IRMD) Non-Current Deferred Tax Liability (2013 - 2023) Analysis & Trends

Iradimed has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $1.1 million in Q4 2023.

Non-Current Deferred Tax Liability for Q4 2023 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $1.1 million (changed N/A YoY), and the FY2023 annual result was $1.1 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability advanced to $1.1 million in Q4 2023, from $611269.0 in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $1.1 million in Q4 2023 and troughed at $1.1 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn
10	Iradimed	1.12 Bn	1.06 Bn	15.16 Mn

Download Data